Mindstate Design Labs is an innovative company focused on exploring and understanding the biological basis of various psychedelic experiences. Their intention is to harness this knowledge in the precision design of modified conscious states for therapeutic purposes. Their work hinges on a unique combination approach, using psychedelic "primer" compounds alongside non-psychedelic "probe" compounds, in an effort to modulate the altered state of consciousness produced by the primer. Their sophisticated target discovery and phenotypic screening platform, Osmanthus, has helped identify six probe candidates, each with potentially unique therapeutic utility. The company's approach is rooted in a blend of natural history, natural language processing, and biochemical data, all of which contribute to building a predictive model for the precision design of altered conscious states. This intricate blend of disciplines is key to their unique methodology and approach, allowing them to map the biological basis of altered conscious states. The essential subjective experience of an altered conscious state is recognized by Mindstate Design Labs as being crucial to therapeutic outcomes. Mindstate Design Labs is led by a highly experienced and diverse team. Dillan DiNardo, a biotechnology investor and operator with a background in venture capital, brings valuable experience from his work in finance and his roles in a $1 billion venture fund. He has managed numerous biopharma, medical device, and health tech investments, and has taken an operating role in multiple early-stage spinout companies. His expertise spans a range of disease indications and modalities, along with a focus on deep-tech applications such as cell and gene therapies. Adding to the expertise within the team, Dr. Ray, an evolutionary biologist, polymath, and iconoclast, contributes his extensive research in the natural history study of psychedelic experiences. His revolutionary work has been featured in reputable media outlets and he has devoted two decades of his career to synthesizing human experience data and biochemical data to understand the biological basis of altered psychedelic experiences. Dr. Wren, a translational pharmacologist, adds further depth to the team with his three decades of global neuroscience R&D experience and senior leadership roles within large pharma. His experience spans target identification, validation, screening, optimization, and clinical pharmacology units.